John Xu
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Genetics top 2%
- Glioma Diagnosis and Treatment
Papers in
-
- Diabetes Treatment and Management 18
- Diabetes Management and Research 10
-
- Inhalation and Respiratory Drug Delivery 2
- Potassium and Related Disorders 1
- Co-authors
- Nevin Ajluni (1 shared paper)Paresh Dandona (9 shared papers)Sergei I. Petrykiv (1 shared paper)Frederik Persson (1 shared paper)Hiddo J.L. Heerspink (1 shared paper)Peter J. Greasley (1 shared paper)C. David Sjöström (1 shared paper)Chantal Mathieu (8 shared papers)
- Journals
- Diabetes Obesity and Metabolism (5 papers)Diabetes (3 papers)Diabetes Care (2 papers)The Lancet Diabetes & Endocrinology (2 papers)Investigational New Drugs (2 papers)
- Partner nations
- United StatesSwedenUnited Kingdom
In The Last Decade
John Xu
26 papers receiving 1.5k citations
John Xu's Hit Papers
Peers
Comparison fields: 5 of 58
- Endocrinology, Diabetes and Metabolism 838
- Genetics 398
- Nephrology 131
- Cardiology and Cardiovascular Medicine 94
- Endocrine and Autonomic Systems 20
Countries citing papers authored by John Xu
This map shows the geographic impact of John Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Xu more than expected).
Fields of papers citing papers by John Xu
This network shows the impact of papers produced by John Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Xu. The network helps show where John Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside John Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma Hit paper breakdown → | 2013 | 488 |
| 2 | 2017 | 248 | |
| 3 | 2018 | 199 | |
| 4 | 2017 | 125 | |
| 5 | 2020 | 62 | |
| 6 | 2016 | 45 | |
| 7 | 2017 | 39 | |
| 8 | 2020 | 38 | |
| 9 | 2017 | 35 | |
| 10 | 2019 | 35 | |
| 11 | 2013 | 34 | |
| 12 | 2017 | 31 | |
| 13 | 2020 | 31 | |
| 14 | 2016 | 28 | |
| 15 | 2015 | 27 | |
| 16 | 2020 | 27 | |
| 17 | 2005 | 24 | |
| 18 | 2010 | 18 | |
| 19 | 2018 | 11 | |
| 20 | 2019 | 8 |
About John Xu
John Xu is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine, Endocrine and Autonomic Systems, Genetics and Nephrology, having authored 29 papers that have together received 1.6k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (18 papers), Diabetes Management and Research (10 papers), Inhalation and Respiratory Drug Delivery (2 papers), Potassium and Related Disorders (1 paper), Systemic Sclerosis and Related Diseases (1 paper), Cancer Immunotherapy and Biomarkers (1 paper), Lipid metabolism and disorders (1 paper) and Glioma Diagnosis and Treatment (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (838 citations), Genetics (398 citations), Nephrology (131 citations), Cardiology and Cardiovascular Medicine (94 citations) and Endocrine and Autonomic Systems (20 citations). John Xu has collaborated with scholars based in United States, Sweden and United Kingdom. Frequent co-authors include Nevin Ajluni, Paresh Dandona, Sergei I. Petrykiv, Frederik Persson, Hiddo J.L. Heerspink, Peter J. Greasley, C. David Sjöström, Chantal Mathieu, FREDRIK A. THOREN and Moshe Phillip. Their work appears in journals such as Diabetes Obesity and Metabolism, Diabetes, Diabetes Care, The Lancet Diabetes & Endocrinology and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.